Using organoid models to predict chemotherapy efficacy: the future of precision oncology?

Patient-derived organoid analysis of drug resistance in precision medicine: is there a value?

“…It is regarded as a transitional model between cancer cell lines and xenografts [28][29][30]. This technique holds great promise for use in the medical field for personalized high-throughput drug screening coupled with genomic analysis (Figure 1) not only to predict resistance to anti-cancer drugs but also to identify effective cancer therapy for individual patients [11,31,32]. Several publications on this topic have been carried ( Table 1), some of which are discussed here.…”

“…To date, the available treatment protocols seem inadequate to prevent the resistance to therapy as well as the recurrence and progression of cancer. Therefore, several experimental models of to study cancer development and progression including rats and mice as well as the in vitro culture models of cell line, 2D cell, induced pluripotent stem cell (iPSCs) lines, spheroids, 3D organoids, organotypic tissue slice cultures, patient-derived tumor xenografts are developed [9][10][11] and certainly, they confer valuable tools for preclinical pharmacological assessment.…”